Application of notoginseng saponins Rg 1 in preparing medicine for treating pulmonary interstitial fibrosis

A technology of pulmonary interstitial fibrosis and notoginseng saponin, applied in the field of application of notoginseng saponin Rgl in the preparation of drugs for the treatment of pulmonary interstitial fibrosis, can solve the problems of high incidence of IPF, achieve good therapeutic effect, and have obvious pharmacological effects , The effect of simple preparation method

Inactive Publication Date: 2010-06-30
XINXIANG MEDICAL UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The incidence of IPF in my country is relatively high, and there is no completely effective drug at present, but notoginseng saponin Rg1 has a significant effect and less side effects, and has a strong development prospect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of notoginseng saponins Rg 1 in preparing medicine for treating pulmonary interstitial fibrosis
  • Application of notoginseng saponins Rg 1 in preparing medicine for treating pulmonary interstitial fibrosis
  • Application of notoginseng saponins Rg 1 in preparing medicine for treating pulmonary interstitial fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 10

[0025] The preparation of embodiment 1 notoginsenoside Rg1 tablet (1000)

[0026] Prescription: Notoginsenoside Rg1 (Kunming Pharmaceutical Factory, the following examples are all the same) 100g, MCC 100g, magnesium stearate 5g.

[0027] Preparation method: Mix notoginseng saponin Rg1 and MCC evenly, moisten with water, pass through a 18-mesh sieve, dry, pass through a 20-mesh sieve again, then add magnesium stearate, mix evenly, and press into tablets.

Embodiment 2 10

[0028] The preparation of embodiment 2 notoginsenoside Rg1 tablet (1000)

[0029] Formula: notoginseng saponin Rg1100g, lactose 120g, carboxymethylcellulose sodium 24g, magnesium stearate 5g.

[0030] Preparation method: mix notoginseng saponin Rg1, lactose and sodium carboxymethylcellulose evenly, moisten with water, pass through a 18-mesh sieve, dry, pass through a 20-mesh sieve again, then add magnesium stearate, mix well, and press into tablets .

Embodiment 3 3

[0031] The preparation of embodiment 3 notoginseng saponin Rg1 capsules (1000 grains)

[0032] Formula: notoginseng saponin Rg1100g, lactose 80g, magnesium stearate 5g.

[0033] Preparation method: mix notoginseng saponin Rg1 and lactose evenly, moisten with water, pass through a 20-mesh sieve, dry, pass through a 22-mesh sieve again, then add magnesium stearate, mix evenly, and pack into capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of notoginseng saponins Rg 1 in preparing medicine for treating pulmonary interstitial fibrosis. Pharmacological experiments show that if in vitro, the notoginseng saponins Rg 1 can inhibit the activity of human embryonic lung fibroblast and has good dose-dependent; if in vivo, the notoginseng saponins Rg 1 can decrease the lung coefficientand the lung hydroxyproline content of a mouse with pulmonary interstitial fibrosis; the notoginseng saponins Rg 1 can also reduce the pulmonary alveolitis and the degree of pulmonary interstitial fibrosis of the mouse with pulmonary interstitial fibrosis; the raw materials of the notoginseng saponins Rg 1 are easy to obtain, and can be prepared into various common dosage forms such as tablets, capsules, and injections; and the preparation method is simple.

Description

technical field [0001] The invention relates to the application of notoginseng saponin Rg1 in the preparation of medicines for treating pulmonary interstitial fibrosis. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) refers to pulmonary interstitial lesions caused by unknown causes, characterized by diffuse alveolitis and alveolar structural disorder, eventually leading to pulmonary interstitial fibrosis. Pulmonary interstitial fibrosis often ends with permanent loss of respiratory function. At present, there is no effective prevention and treatment method, which seriously threatens the life and quality of life of patients. The disease of acute patients develops rapidly. The rate is also very low; and chronic patients only have a course of disease of about 15 years. [0003] The morbidity and mortality of idiopathic pulmonary interstitial fibrosis and pulmonary interstitial fibrosis with definite etiology (such as infection, poison, drug, environmental pol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P11/00
Inventor 詹合琴郭兰青张小毅尹雅玲海广范刘巨源刘俊扇
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap